98%
921
2 minutes
20
Catalytic effect of metal ions on luminol chemiluminescence (CL) was investigated by sequential injection analysis (SIA). The SIA system was set up with two solenoid micropumps, an eight-port selection valve, and a photosensor module with a fountain-type chemiluminescence cell. The SIA system was controlled and the CL signals were collected by a LabVIEW program. Aqueous solutions of luminol, H(2)O(2), and a sample solution containing metal ion were sequentially aspirated to the holding coil, and the zones were immediately propelled to the detection cell. After optimizing the parameters using 1 x 10(-5)M Fe(3+) solution, catalytic effect of some metal species was compared. Among 16 metal species examined, relatively strong CL responses were obtained with Fe(3+), Fe(2+), VO(2+), VO(3)(-), MnO(4)(-), Co(2+), and Cu(2+). The limits of detection by the present SIA system were comparable to FIA systems. Permanganate ion showed the highest CL sensitivity among the metal species examined; the calibration graph for MnO(4)(-) was linear at the concentration level of 10(-8)M and the limit of detection for MnO(4)(-) was 4.0 x 10(-10)M (S/N=3).
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.talanta.2009.03.024 | DOI Listing |
Heart
September 2025
Department of Cardiology, National University Heart Centre Singapore, Singapore
Background: There is limited contemporary data available on the subject of left ventricular thrombus (LVT) recurrence. This study aimed to evaluate the incidence, outcomes and predictors of patients with LVT recurrence after resolution.
Methods: This was a retrospective cohort study involving 346 patients with resolved LVT at baseline, derived from an echocardiography database at a tertiary medical centre, from March 2011 to January 2021.
Nanomicro Lett
September 2025
State Key Laboratory of Robotics and Intelligent Systems, Shenyang Institute of Automation, Chinese Academy of Sciences, Shenyang, 110016, People's Republic of China.
In the realm of secure information storage, optical encryption has emerged as a vital technique, particularly with the miniaturization of encryption devices. However, many existing systems lack the necessary reconfigurability and dynamic functionality. This study presents a novel approach through the development of dynamic optical-to-chemical energy conversion metamaterials, which enable enhanced steganography and multilevel information storage.
View Article and Find Full Text PDFCirculation
September 2025
Department of Medicine, Stanford University, CA (D.J.M.).
Background: In ISCHEMIA (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches), an invasive strategy demonstrated better health status outcomes than a conservative strategy in patients with chronic coronary disease (CCD). Some previous studies have shown greater health status benefits with coronary artery bypass grafting (CABG) than percutaneous coronary intervention (PCI). Whether the health status benefits of invasive management in ISCHEMIA were driven primarily by participants treated with CABG is unknown.
View Article and Find Full Text PDFTalanta
August 2025
Department of Molecular Tropical Medicine and Genetics, Faculty of Tropical Medicine, Mahidol University, Bangkok, 10400, Thailand. Electronic address:
A rapid and automated determination of nicotinamide adenine dinucleotide phosphate (NADPH) is proposed and applied to the evaluation of glucose-6-phosphate dehydrogenase (G6PD) deficiency in real samples. To this end, a sequential injection analyzer with electrochemical detection (SIA-ECD) is proposed with 0.1 mol L Tris-HCl (pH 8.
View Article and Find Full Text PDFLancet
August 2025
Université de Lorraine, Inserm CIC 1433, CHRU, Nancy, France.
Background: Vericiguat is indicated to reduce the risk of cardiovascular death and hospitalisation for heart failure in patients with heart failure and reduced ejection fraction (HFrEF) following a recent worsening event. The aim of the VICTOR trial was to assess the effect of vericiguat in patients with HFrEF without recent heart failure worsening.
Methods: In this double-blind, placebo-controlled, phase 3 trial, conducted at 482 sites across 36 countries, patients aged 18 years or older with HFrEF (left ventricular ejection fraction of ≤40%) without heart failure hospitalisation within 6 months or outpatient intravenous diuretic use within 3 months before randomisation were randomly assigned (1:1) using an intervention randomisation system with interactive response technology to oral vericiguat (target 10 mg dose) or matching placebo.